Stay updated on Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC Clinical Trial
Sign up to get notified when there's something new on the Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC Clinical Trial page.

Latest updates to the Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check15 days agoChange DetectedRevision label updated to v3.4.3, replacing the previous v3.4.2 revision.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedStatus updated to Terminated with <75% participation and related dates; an Informed Consent Form PDF is now listed under Study Documents (M.D. Anderson Cancer Center).SummaryDifference1%

- Check43 days agoChange DetectedAdministrative site updates were made: Revision: v3.4.2 was added and an older notice (Revision: v3.4.1) was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check50 days agoChange DetectedAdded a government funding lapse notice with references to cc.nih.gov and opm.gov, and updated the site version to v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check58 days agoChange DetectedThe page now displays the study completion and primary completion dates as 2027-12-31, and the latest update posted date as 2026-01-27. A new 'Show glossary' option has been added to the page.SummaryDifference0.6%

Stay in the know with updates to Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC Clinical Trial page.